The list price of GLP-1 drugs is not what most people pay.
| Stat | Value |
|---|---|
| Ozempic list price (before any savings) | ~$936/mo |
| Cost with Novo Nordisk or Lilly savings card (eligible patients) | ~$25/mo |
| Cost through Patient Assistance Programs for qualifying uninsured patients | $0 |
| Typical manufacturer savings card duration before expiration | 12–24 mo |
Key Takeaways
- List prices: Ozempic ~$936/month, Wegovy ~$1,349/month, Mounjaro ~$1,023/month, Zepbound ~$550/month — before any discount program.
- Manufacturer savings cards: Novo Nordisk and Eli Lilly both offer cards that can bring monthly cost to ~$25 for eligible commercially insured patients.
- GoodRx limitation: GoodRx typically does not beat manufacturer pricing on GLP-1s — always compare before using it.
- Patient Assistance Programs: NovoCare and Lilly Cares can provide medication at no cost for uninsured or underinsured patients who meet income criteria.
- Telehealth bundling: Some platforms include medication + consultation for $200–$400/month total — often less than the drug alone at retail.
- Honest limitation: No coupon or savings card survives Medicare enrollment. Patients who transition to Medicare lose access to manufacturer cards entirely.
The gap between the sticker price on GLP-1 drugs and what a patient actually pays can be thousands of dollars a year. That gap depends on which program you're using, whether you have commercial insurance, and how long you've been on the drug. Most patients navigate this without a clear map. This guide lays out every major savings mechanism, what each one requires, and where each one runs out.
What GLP-1 drugs actually cost at list price
These numbers are deliberately visible because they frame everything else.
Ozempic (semaglutide, approved for type 2 diabetes) runs approximately $936 per month at full retail. Wegovy (semaglutide 2.4mg, approved for obesity) lists at approximately $1,349 per month. Mounjaro (tirzepatide, T2D) sits around $1,023 per month. Zepbound (tirzepatide, obesity) lists at approximately $550 per month — lower than the others partly because Lilly set a more competitive launch price to capture market share.
Saxenda (liraglutide 3mg, obesity) lists near $1,430 per month. Rybelsus (oral semaglutide, T2D) runs roughly $936 per month.
Almost no one with commercial insurance pays these prices. But people without insurance — or people on Medicare — face them directly unless they find alternatives. Understanding the full savings landscape matters for both groups.
Manufacturer savings cards: how they work
Both Novo Nordisk and Eli Lilly offer savings cards, and the details differ by drug.
Novo Nordisk's Ozempic Savings Card can bring the monthly out-of-pocket cost to approximately $25 for eligible patients — with a cap on monthly savings that varies by dose. The Wegovy WeightLoss Coupon program has a similar structure. Rybelsus has its own savings card through the same program. These cards are applied at the pharmacy at the time of pickup and work by having the manufacturer subsidize the difference between what your insurance pays and what you owe.
Eli Lilly's Mounjaro Savings Card (for T2D patients) and Zepbound savings card follow the same model — approximately $25 per month for eligible patients. Lilly has periodically run more aggressive promotional offers for Zepbound with lower first-month pricing as well.
The $25/month figure is real for eligible patients — but "eligible" has a specific definition. You must have commercial insurance that covers the drug. If your insurance does not cover the specific drug, the savings card may not work, or may have a different savings cap. Always confirm with the manufacturer's program before assuming the $25 price applies to your situation.
Eligibility requirements for manufacturer cards
The requirements are consistent across both manufacturers.
First: you must have commercial insurance. Government insurance (Medicare, Medicaid, TRICARE) disqualifies you from using manufacturer savings cards — federal anti-kickback regulations prohibit these arrangements for federally funded insurance. This is not a manufacturer choice; it is a legal constraint.
Second: your insurance must cover the specific drug being prescribed. A Wegovy savings card does not help if your insurance doesn't cover Wegovy at all. In that case, the card may still cap your cost at a higher amount, but the $25 figure typically requires at least some insurance contribution.
Third: some cards have income ceilings or monthly/annual savings caps. Read the terms of the specific program — Novo Nordisk and Eli Lilly both have program pages where current terms are posted.
GoodRx and GLP-1 drugs: the honest picture
GoodRx rarely wins on GLP-1s.
GoodRx works by negotiating pharmacy benefit manager pricing and passing discounts to consumers. For many generic medications, GoodRx prices are genuinely lower than what patients pay at the pharmacy. GLP-1 drugs are different. Manufacturer savings cards typically produce lower prices than GoodRx on Ozempic, Wegovy, Mounjaro, and Zepbound for patients with commercial insurance. For patients without insurance, GoodRx pricing on these drugs may still reach $800–$900+ per month.
That does not mean GoodRx is useless here. It is always worth checking — pricing varies by pharmacy, and in some cases GoodRx prices at specific pharmacies may beat other options. But if you're comparing GoodRx against a manufacturer savings card, run the numbers specifically rather than assuming GoodRx is cheaper.
Mark Cuban's Cost Plus Drugs: what it does and doesn't cover
Cost Plus Drugs doesn't carry brand-name GLP-1s.
The platform, which offers generic and some specialty medications at near-cost pricing, does not stock Ozempic, Wegovy, Mounjaro, or Zepbound. This is largely because these are still under patent protection and manufactured by two companies that have no reason to supply them to a low-margin platform. Compounded semaglutide has also not been available there. If Cost Plus Drugs becomes relevant to GLP-1 access in the future, that will likely coincide with patent expirations and the emergence of generic semaglutide — which is years away.
Patient Assistance Programs: the free medication option
Both major manufacturers have programs for uninsured or underinsured patients.
NovoCare Patient Assistance Program covers Ozempic, Wegovy, Rybelsus, Victoza, and Saxenda. Lilly Cares Foundation covers Mounjaro, Zepbound, and Trulicity. Both programs are income-based — eligibility typically requires income below 400–600% of the federal poverty level, though the specific threshold changes and should be verified directly with each program.
For patients who qualify, these programs can provide medication at no cost. The application process involves income documentation and a physician signature. Processing time ranges from two to six weeks. These programs are not well-publicized, which is why many patients who would qualify are never told they exist.
If you are uninsured and your household income is under approximately $60,000 (for a single person) or $120,000 (for a family of four), you likely qualify for at least one Patient Assistance Program. This is worth applying for before paying retail price or going without medication.
Telehealth bundled pricing: the math that changes the comparison
Some telehealth platforms restructure the cost equation entirely.
Instead of billing separately for consultation, labs, and medication, several platforms offer a monthly subscription that includes clinical visits and either a direct-fill of compounded semaglutide or a co-pay assistance arrangement for branded drugs. The total monthly cost at some of these platforms runs $200–$400 per month — often less than the out-of-pocket cost of the drug alone at a traditional pharmacy without a savings card.
The tradeoff is that these platforms may be using compounded semaglutide rather than branded Ozempic or Wegovy. Compounded semaglutide from 503A or 503B pharmacies became a significant access route during the period when branded semaglutide was on the FDA shortage list. The FDA shortage designation for semaglutide changed in 2025, which affected the legal availability of compounded versions — consult your provider for current status in your state.
Insurance prior authorization: how to get it approved
Prior authorization is the main access barrier for insured patients.
PA requires your physician to submit a formal request to your insurance company demonstrating that the medication is medically necessary. The documentation typically includes your BMI measurement, documentation of any qualifying comorbidities, and — in many cases — documentation that you have already attempted other weight loss treatments (usually including lifestyle intervention, and sometimes prior medications).
The "failure of prior therapy" requirement trips up many patients. Some insurance plans deny GLP-1 coverage unless the patient can document that a previous weight loss intervention didn't produce adequate results. If you have not done this formally through your physician's office, that documentation may be missing from your chart, which leads to denial. Working with a provider who is experienced in GLP-1 PA submissions — and who has a process for gathering the right documentation upfront — significantly increases first-attempt approval rates.
| Savings Option | Typical Monthly Cost | Who Qualifies | Key Limitation |
|---|---|---|---|
| Manufacturer savings card (Novo/Lilly) | ~$25 | Commercially insured patients | No Medicare/Medicaid; expires in 12–24 months |
| GoodRx | $800–$950 (varies by pharmacy) | Anyone | Usually not competitive vs. manufacturer cards |
| Patient Assistance Program | $0 | Uninsured/underinsured, income-based | Application time 2–6 weeks; income limits apply |
| Telehealth bundled pricing | $200–$400 (all-in) | Anyone; no insurance required | May involve compounded vs. branded drug |
| Insurance with PA approval | Copay ($0–$100) | Commercially insured, qualifying diagnosis | PA required; prior treatment documentation needed |
When your savings card expires: planning ahead
Manufacturer savings cards run for a defined period — typically 12 to 24 months.
When a card expires, the monthly cost jumps back to your insurance copay (which could be significant) or to a higher out-of-pocket amount if coverage has changed. Most patients don't plan for this and are caught off-guard. The time to address it is several months before expiration — by checking whether a new savings card has been issued (programs do renew them), whether your insurance plan has changed its coverage tier for the drug, or whether the telehealth bundled route produces a lower all-in cost at that point.
Some manufacturers issue updated cards for patients who have been on the drug continuously. Calling the manufacturer's program directly — NovoCare at 1-833-NOVO-411 or Lilly Cares at 1-800-545-5979 — is the most reliable way to understand current options specific to your situation.
The honest limitation: Medicare patients face a structural wall
No coupon survives Medicare enrollment, and this is not a workaround problem.
Federal law prohibits manufacturers from offering savings cards or discount programs to Medicare beneficiaries. The intent of this rule is to prevent pharmaceutical companies from influencing drug selection for federally insured patients. The practical effect is that when a patient turns 65 and enrolls in Medicare — or when they qualify for Medicare due to disability before 65 — their existing savings card stops working immediately.
For Medicare patients, the relevant savings mechanisms are different: Medicare Part D Extra Help (Low Income Subsidy) for patients below certain income thresholds, and the Medicare negotiated pricing for drugs that have entered the price negotiation process. Wegovy was included in the first round of Medicare drug price negotiations authorized under the Inflation Reduction Act, with negotiated prices taking effect in 2026. The negotiated price is significantly below list price, though still higher than what commercially insured patients pay with manufacturer cards.
Frequently Asked Questions
Do the manufacturer savings cards work at any pharmacy?
Most major retail pharmacies accept the cards — CVS, Walgreens, Rite Aid, Walmart, Costco, and most grocery store pharmacies. Mail-order pharmacies through your insurance plan may also accept them, but this varies. Specialty pharmacies used by some insurance plans may have different arrangements. Confirm with the specific pharmacy before assuming it works.
Can I use a manufacturer savings card if my insurance doesn't cover the drug?
This depends on the specific card. Some manufacturer savings cards have a "no insurance" rate — a separate cap that applies when you have no insurance coverage for the drug. This cap is usually higher than the ~$25 insured rate, but still well below list price. Check the manufacturer's program terms for the specific number.
Is there a way to get GLP-1s for free permanently?
No program guarantees permanent free access. Patient Assistance Programs are income-based and can be discontinued if your financial situation changes or if program funding changes. The most stable long-term cost solution for most patients is having commercial insurance that covers the drug — which shifts cost to a predictable copay — combined with a manufacturer card while it's available.
What happens if my insurance denies prior authorization?
You have the right to appeal. The first step is a peer-to-peer review, where your physician speaks directly with the insurer's medical reviewer. Approval rates on appeal are meaningfully higher than initial denial rates. If appeal fails, you can request an external review by an independent organization. In the meantime, most manufacturers have a bridge supply program that provides a short-term supply while the PA is being appealed.
Are compounded GLP-1 options still available in 2026?
The FDA removed semaglutide from its drug shortage list in 2025, which changed the legal landscape for compounded versions. Access to compounded semaglutide now depends on the specific 503A or 503B pharmacy and state regulations. Your provider will have the most current information on what is available and compliant in your location. Compounded tirzepatide has had a different regulatory timeline.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any medication.
